search
Back to results

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

Primary Purpose

Hypertension

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Lisinopril, Atenolol
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring High blood pressure

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female hypertensive participants who were previously studied in SCOR program.

Exclusion Criteria:

  • Diabetes
  • Taking other medications beside thyroid or estrogen supplements.

Sites / Locations

  • Brigham and Women's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lisinopril, Atenolol

Arm Description

Outcomes

Primary Outcome Measures

One type of blood pressure medication will better treat individuals with certain genetic backgrounds.

Secondary Outcome Measures

Full Information

First Posted
November 6, 2009
Last Updated
April 7, 2021
Sponsor
Brigham and Women's Hospital
Collaborators
University of Utah
search

1. Study Identification

Unique Protocol Identification Number
NCT01009944
Brief Title
Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
Official Title
Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Not funded.
Study Start Date
January 2007 (Actual)
Primary Completion Date
March 19, 2019 (Actual)
Study Completion Date
March 19, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
University of Utah

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
High blood pressure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lisinopril, Atenolol
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Lisinopril, Atenolol
Other Intervention Name(s)
Tenormin (Atenolol), Prinivil, Zestril (Lisinopril)
Intervention Description
once a day for 14 weeks
Primary Outcome Measure Information:
Title
One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female hypertensive participants who were previously studied in SCOR program. Exclusion Criteria: Diabetes Taking other medications beside thyroid or estrogen supplements.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gordon H. Williams, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

We'll reach out to this number within 24 hrs